| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| High-Throughput Nucleotide Sequencing | 11 | 2024 | 2348 | 0.850 |
Why?
|
| Mutation | 21 | 2021 | 15640 | 0.620 |
Why?
|
| Medulloblastoma | 3 | 2018 | 590 | 0.540 |
Why?
|
| Cerebellar Neoplasms | 2 | 2018 | 488 | 0.540 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10641 | 0.460 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 1916 | 0.450 |
Why?
|
| Brain Neoplasms | 7 | 2019 | 5019 | 0.440 |
Why?
|
| Glioblastoma | 6 | 2019 | 1845 | 0.440 |
Why?
|
| Neuroblastoma | 1 | 2018 | 695 | 0.410 |
Why?
|
| Circulating Tumor DNA | 3 | 2021 | 257 | 0.400 |
Why?
|
| Skin Neoplasms | 5 | 2019 | 4744 | 0.390 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1369 | 0.340 |
Why?
|
| Trehalase | 3 | 2005 | 5 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 4 | 2021 | 2496 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2017 | 5298 | 0.280 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2657 | 0.280 |
Why?
|
| Genomics | 6 | 2021 | 2845 | 0.280 |
Why?
|
| DNA Copy Number Variations | 5 | 2021 | 1540 | 0.270 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 5228 | 0.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 9065 | 0.250 |
Why?
|
| Neoplasms | 8 | 2021 | 15797 | 0.240 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 16073 | 0.240 |
Why?
|
| Precision Medicine | 3 | 2021 | 1213 | 0.200 |
Why?
|
| Benchmarking | 1 | 2024 | 290 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 4921 | 0.200 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 180 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 3660 | 0.170 |
Why?
|
| Methyltransferases | 1 | 2010 | 149 | 0.160 |
Why?
|
| Melanoma | 4 | 2018 | 5393 | 0.160 |
Why?
|
| Mucor | 2 | 2000 | 18 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 16327 | 0.160 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 175 | 0.160 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 66 | 0.160 |
Why?
|
| Patient Participation | 1 | 2012 | 478 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 150 | 0.160 |
Why?
|
| Lysine | 1 | 2010 | 429 | 0.160 |
Why?
|
| Prognosis | 7 | 2021 | 22348 | 0.160 |
Why?
|
| Autophagy-Related Proteins | 1 | 2018 | 55 | 0.150 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2008 | 31 | 0.150 |
Why?
|
| Oncogenes | 1 | 2021 | 674 | 0.150 |
Why?
|
| Humans | 40 | 2024 | 270969 | 0.150 |
Why?
|
| Hemangioma | 1 | 2019 | 160 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 525 | 0.140 |
Why?
|
| Middle Aged | 22 | 2021 | 89661 | 0.140 |
Why?
|
| Adult | 20 | 2021 | 80872 | 0.140 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 14558 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 490 | 0.140 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 211 | 0.140 |
Why?
|
| Female | 26 | 2020 | 147624 | 0.140 |
Why?
|
| Laboratories | 1 | 2017 | 140 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2508 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 366 | 0.130 |
Why?
|
| Heterografts | 2 | 2015 | 751 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2018 | 254 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2019 | 10282 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2017 | 508 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 494 | 0.130 |
Why?
|
| Astrocytoma | 1 | 2008 | 333 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 395 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 264 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 366 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 695 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2298 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2013 | 6221 | 0.130 |
Why?
|
| Inosine | 1 | 2015 | 40 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 383 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2021 | 1673 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 707 | 0.120 |
Why?
|
| Aged | 16 | 2021 | 73018 | 0.120 |
Why?
|
| Cadherins | 1 | 2008 | 669 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 11638 | 0.120 |
Why?
|
| Decision Making | 1 | 2012 | 1341 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1283 | 0.120 |
Why?
|
| Research | 1 | 2017 | 434 | 0.120 |
Why?
|
| RNA Editing | 1 | 2015 | 91 | 0.120 |
Why?
|
| Computational Biology | 4 | 2024 | 1281 | 0.120 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 317 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2014 | 41 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 512 | 0.120 |
Why?
|
| Genes, ras | 1 | 2017 | 670 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 4458 | 0.120 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2015 | 361 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 623 | 0.110 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 30845 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 135 | 0.110 |
Why?
|
| Cerebellum | 1 | 2018 | 467 | 0.110 |
Why?
|
| Fungi | 1 | 2005 | 147 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 867 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1186 | 0.110 |
Why?
|
| Histones | 1 | 2010 | 1493 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 1446 | 0.110 |
Why?
|
| Adenosine | 1 | 2015 | 294 | 0.110 |
Why?
|
| Trehalose | 2 | 2000 | 25 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 1575 | 0.110 |
Why?
|
| Cell Wall | 2 | 2000 | 48 | 0.110 |
Why?
|
| Uveal Neoplasms | 1 | 2015 | 190 | 0.110 |
Why?
|
| Genome, Human | 2 | 2019 | 1853 | 0.100 |
Why?
|
| Philadelphia Chromosome | 1 | 2016 | 828 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 4329 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2021 | 1479 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2081 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 549 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 424 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2017 | 1559 | 0.100 |
Why?
|
| Gallbladder Neoplasms | 1 | 2013 | 248 | 0.100 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 14928 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 1475 | 0.090 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 1806 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 5121 | 0.090 |
Why?
|
| ras Proteins | 1 | 2015 | 784 | 0.090 |
Why?
|
| Brain | 3 | 2008 | 4219 | 0.090 |
Why?
|
| Glioma | 2 | 2019 | 2001 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2392 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 3962 | 0.090 |
Why?
|
| Infant | 4 | 2018 | 13889 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 1009 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 4940 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5458 | 0.090 |
Why?
|
| Gene Expression | 1 | 2008 | 3574 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 637 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 3954 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2006 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2017 | 2035 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 3362 | 0.080 |
Why?
|
| Mice, Nude | 4 | 2015 | 4341 | 0.080 |
Why?
|
| Male | 17 | 2021 | 127769 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 1331 | 0.070 |
Why?
|
| Gene Regulatory Networks | 2 | 2013 | 677 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2018 | 2729 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1307 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 7711 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 2388 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6034 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 4720 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3621 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2018 | 3636 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2564 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6181 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 2020 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2019 | 13336 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15255 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6269 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 13883 | 0.060 |
Why?
|
| INDEL Mutation | 1 | 2024 | 115 | 0.060 |
Why?
|
| Animals | 10 | 2017 | 61175 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2017 | 1125 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 5250 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7982 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 2869 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2020 | 9311 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2016 | 3518 | 0.050 |
Why?
|
| Mice | 7 | 2017 | 35455 | 0.050 |
Why?
|
| Adolescent | 6 | 2018 | 32464 | 0.050 |
Why?
|
| Quality Control | 1 | 2024 | 459 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 3098 | 0.050 |
Why?
|
| Enzyme Stability | 2 | 2005 | 109 | 0.050 |
Why?
|
| Edetic Acid | 2 | 2005 | 71 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2010 | 948 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 83 | 0.050 |
Why?
|
| Butyrate Response Factor 1 | 1 | 2010 | 6 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2018 | 16882 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10092 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2017 | 1072 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 4084 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2005 | 598 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2015 | 1865 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2018 | 9466 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2010 | 106 | 0.040 |
Why?
|
| Temperature | 2 | 2005 | 519 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5495 | 0.040 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2009 | 17 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 23 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2013 | 751 | 0.040 |
Why?
|
| Cell Movement | 2 | 2015 | 2510 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 5431 | 0.040 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2009 | 55 | 0.040 |
Why?
|
| Tissue Embedding | 1 | 2019 | 29 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 4064 | 0.040 |
Why?
|
| Boston | 1 | 2019 | 107 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Methylation | 1 | 2010 | 598 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 170 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7333 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 128 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 343 | 0.040 |
Why?
|
| Epidermal Cyst | 1 | 2018 | 46 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 559 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 489 | 0.040 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2018 | 65 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 196 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 533 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7877 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 275 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 1080 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 992 | 0.040 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 464 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 336 | 0.040 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2017 | 111 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 1165 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 506 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2017 | 188 | 0.030 |
Why?
|
| Child | 4 | 2018 | 30357 | 0.030 |
Why?
|
| Calibration | 1 | 2007 | 340 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 376 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1502 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 206 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2016 | 184 | 0.030 |
Why?
|
| Disease Progression | 2 | 2019 | 6881 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 290 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 375 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 317 | 0.030 |
Why?
|
| Pronase | 1 | 2005 | 5 | 0.030 |
Why?
|
| Algorithms | 2 | 2017 | 3980 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2018 | 626 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 95 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 688 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2015 | 60 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 1699 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1118 | 0.030 |
Why?
|
| Dasatinib | 1 | 2018 | 879 | 0.030 |
Why?
|
| DNA Primers | 1 | 2007 | 1413 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 73 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 68 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 522 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 796 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 622 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 218 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 1690 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 192 | 0.030 |
Why?
|
| Tongue Neoplasms | 1 | 2016 | 252 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 183 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 905 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2010 | 3376 | 0.030 |
Why?
|
| Luciferases | 1 | 2015 | 454 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 576 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1340 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2015 | 214 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 342 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 308 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2198 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 139 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2013 | 113 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 271 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2009 | 3594 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 225 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2015 | 592 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 883 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 580 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 810 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2016 | 663 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2019 | 34335 | 0.030 |
Why?
|
| Glucose | 2 | 2000 | 1272 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 522 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 386 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 382 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 738 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 22268 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1269 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2016 | 754 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 1533 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2371 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2337 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1263 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 5021 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2016 | 727 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2487 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 2406 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 13261 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 5510 | 0.020 |
Why?
|
| Anaerobiosis | 1 | 2000 | 23 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 832 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 1472 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 2987 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2000 | 250 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 1588 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 91 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 12475 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 795 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1125 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 5498 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 4061 | 0.020 |
Why?
|
| Culture Media | 1 | 2000 | 323 | 0.020 |
Why?
|
| DNA Damage | 1 | 2017 | 1983 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 1008 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 263 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3234 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5893 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 4903 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1528 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1379 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 5094 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2131 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 1963 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6107 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3218 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5161 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 2398 | 0.020 |
Why?
|
| Extracellular Space | 1 | 1997 | 134 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3968 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6489 | 0.020 |
Why?
|
| Cytosol | 1 | 1997 | 235 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1997 | 369 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 1907 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 5015 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 7105 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 569 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2629 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 7456 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1997 | 1800 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 7756 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6353 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 5156 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 2961 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 1554 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2015 | 5360 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 18036 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1997 | 4887 | 0.010 |
Why?
|
| United States | 1 | 2015 | 16325 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 12145 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 39724 | 0.010 |
Why?
|